DEPDC1 (DEP Domain-Containing Protein 1) is a protein-coding gene implicated in cell cycle regulation and carcinogenesis. It belongs to the GATOR1 complex, which negatively regulates the mTORC1 signaling pathway, a critical regulator of cell growth and metabolism. Dysregulation of DEPDC1 has been linked to tumor progression, with overexpression observed in various cancers, including bladder, liver, and breast cancers, where it correlates with poor prognosis. Antibodies targeting DEPDC1 are essential tools for investigating its expression, localization, and functional roles in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels in clinical samples or experimental models. Research suggests DEPDC1 may serve as a potential biomarker for cancer diagnosis or a therapeutic target, driving interest in developing specific and validated antibodies. Commercial DEPDC1 antibodies are typically raised against epitopes within its conserved N-terminal or C-terminal regions, with validation including knockout cell line controls. However, variability in antibody performance across applications requires careful optimization. Ongoing studies focus on elucidating DEPDC1’s interplay with mTOR-related pathways and its impact on cancer cell proliferation, apoptosis, and drug resistance.